Press releases

Reinforcing company's ongoing commitment to leadership in the global medical technology market.

REPRISE II data honored as Best Abstract 2013 at PCR London valves course

Represents significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™ Stent System.

Unlike medications alone, bronchial thermoplasty provides benefits that last for years rather than hours

Boston Scientific will participate in the healthcare conference on September 11 in Boston. Learn how to watch the webcast or replay.

Boston Scientific will participate in the healthcare conference on September 9 in New York. Learn how to watch the webcast or replay.

First implantations in Zhejiang province and Beijing mark the launch of the COGNIS CRT-D in the Chinese market.

Products join the company's growing portfolio of next generation EP tools designed to redefine ablation technology.

Innovative bare metal stent designed to treat Peripheral Artery Disease.

Public offering consists of $600 million of 2.650% notes due October 1, 2018 and $450 million of 4.125% notes due October 1, 2023.

Company expects to receive the net offering proceeds upon closing on August 13, 2013, subject to customary closing conditions.

"As we continue to expand our portfolio, our team is inspired to deliver meaningful innovation to more patients globally," said president and CEO Mike Mahoney.

System is next-generation 3D mapping and navigation solution for use in cardiac catheter ablations and other electrophysiology (EP) procedures.

Next generation intravascular ultrasound catheter improves image quality and deliverability

First patient treated in OPTIMISE clinical trial evaluating safety, efficacy of occipital nerve stimulation using Precision™ system.

Device facilitates delivery of interventional devices in complex PCI procedures.

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 ended June 30, 2013. Learn how to tune in.

Transaction to accelerate Boston Scientific expansion in growing electrophysiology market

Cardiac pacing device also features technology to help identify patients with severe sleep apnea.

New family of pacemakers monitor respiration, adjust pacing accordingly, and support insight into the patient’s overall heart failure status.

Outcomes follow recent NICE guidance supporting safety and effectiveness of subcutaneous implantable defibrillators.

VANTAGE study interim data presented at International Congress of Parkinson's Disease and Movement Disorders in Sydney.

Boston Scientific Corporation (NYSE: BSX) announces the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. ...

Company continues to demonstrate its commitment to women's health with a research and education grant of more than $1 million for the SUPeR clinical trial.

GUIDE DBS is the world's first Deep Brain Stimulation visual simulation system.

Boston Scientific will participate in the healthcare conference on May 30 in Boston. Learn how to watch the webcast or replay.

Interim data from REDUCE-HTN clinical program presented today at EuroPCR

New data presented in late-breaking clinical trial session at EuroPCR demonstrated successful deployment of the Lotus™ Valve in the first 60 patients with minimal paravalvular regurgitation at 30 days.

Positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease.

Bronchial Thermoplasty shown to provide long term asthma control over a five-year period after treatment.

More than 24 clinical presentations will feature new data and analyses on Boston Scientific endoscopy products.

Company to present a diversified set of data at the annual EuroPCR Scientific Program May 21-24 in Paris.

Study evaluates clinical outcomes of self-expanding metal stents as a bridge to surgery.

Industry-leading battery life reduces the frequency of replacement surgery.

Company offers mapping system with IntellaMap Orion™ mapping catheter in effort to significantly enhance physician treatment options.

Clinical trial data demonstrated significant reductions in both cardiovascular and all death compared to warfarin.

Boston Scientific will participate in the healthcare conference on May 15 in Las Vegas. Learn how to watch the webcast or replay.

New line of ablation catheters for treating type 1 atrial flutter is designed to provide physicians with high resolution, precise, multidimensional information.

Forty-two clinical presentations will provide new insights about Boston Scientific research in cardiovascular disease, including atrial fibrillation and sudden cardiac arrest.

"We continue to be encouraged but not satisfied with our operating performance," said CEO Mike Mahoney.

Earth Week celebration focuses on 3,900-panel project at the company’s international distribution center in Quincy.

Innovative device quickly anchors leads and catheters.

SAMURAI study designed to confirm the safety and effectiveness of ImageReady™ MR Conditional pacing system in the magnetic resonance imaging (MRI) environment.

World's first and only system with Illumina 3D™ software and 32 contacts is designed to provide pain relief to a broad spectrum of chronic pain patients.

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 ended March 31, 2013. Learn how to tune in.

Results Revealed at CIT 2013

Deadly but preventable cancer is a focus during colorectal cancer awareness month

Separate study demonstrates PROMUS Element stent has significantly less vessel straightening than the Xience V® stent.

WATCHMAN® device continues to demonstrate positive clinical outcomes for patients with atrial fibrillation.

Preliminary data in PREVAIL clinical trial met two out of three co-primary endpoints.